Line Hartvig

Line Hartvig is a seasoned professional in drug discovery and nonclinical development, currently serving as a Senior Nonclinical Advisor at Breye Therapeutics ApS since December 2022 and as an External Senior Nonclinical Advisor at KLIFO. Line also operates as an independent nonclinical consultant through Lhartvig since April 2012. In addition to these roles, Line is a member of the Expert Panel at Innovation Fund Denmark’s InnoExplorer program and a jury member at the EIC Transition for EISMEA. Previous positions include Head of Nonclinical Development at Rewind Therapeutics and toxicologist at Novo Nordisk. Line's educational background includes a Ph.D. earned from the University of Copenhagen, supplemented by ongoing doctoral studies at Aarhus University.